Short answer: on 28 September 2026 the FDA confirmed it is reviewing the premarket tobacco product application (PMTA) framework it has run since 2021, and said it may open a rulemaking process that could replace it. Nothing changed that day. Applications are still being processed and marketing decisions are still being issued. But the single rule that decides which vapor products a US distributor, chain or online seller may legally stock is now formally under review – and that is a purchasing problem for anyone writing Q1 2027 purchase orders in the next ninety days.
This is a different story from the state-level rules that reshaped US assortments through 2026. This one sits in three places at once: the federal framework, the import alert that decides what gets held at the border, and the state directories that decide what is allowed on a shelf.
What the FDA actually said on 28 September
The statement was short and deliberately undramatic. The agency said it is evaluating its experience implementing the PMTA rule, recent court developments, the growth of the illicit and unregulated market, and the pace of new product introductions.
It then used the sentence that matters commercially. The FDA said it believes “a modern framework that reflects current market realities and provides greater clarity and predictability is critical to maximizing the protection of public health,” and that it intends to evaluate possible changes, including a new rulemaking process that could replace the current system.
Two things the statement did not say. It did not give a date. And it did not pause anything. The FDA said explicitly that no immediate operational changes are being introduced, and that it will keep processing PMTA submissions, conducting premarket reviews and issuing marketing decisions under the Tobacco Control Act and the “appropriate for the protection of public health” standard.
The Wall Street Journal had earlier reported that the agency was preparing measures to accelerate review of vaping products and nicotine pouches, potentially including simplified scientific evidence requirements and shorter review timelines. The FDA’s own statement framed those reports as direction of travel rather than an operating change already in force.
Three reasons the framework is being reopened
1. A federal lawsuit in Texas
The FDA named court developments directly, including a federal lawsuit in Texas challenging the current regulatory framework. When a rule is being litigated, agencies have an incentive to rebuild it on firmer statutory ground rather than defend it case by case. A rewrite started under litigation pressure tends to be more prescriptive about evidence and timelines, not less – which cuts both ways for importers.
2. The unregulated market got bigger, not smaller
Industry estimates circulated in 2026 put unauthorized product at roughly 70% of the US vapor market by volume. Five years of enforcement letters and import detentions did not move that number in the direction regulators wanted. The stated drivers of the review – implementation experience plus “the growth of the illicit and unregulated market” – are an admission that the current gatekeeping mechanism is not doing the gatekeeping.
3. Authorizations already started moving in a different direction
In May 2026 the FDA authorized four Glas e-liquid pods – tobacco, menthol and two fruit flavors. Those were the agency’s first PMTA authorizations for non-tobacco, non-menthol flavored ENDS, which broke a long-standing pattern. On 28 August 2026 the agency authorized three products in the JUUL2 system: the device, a tobacco-flavored pod and a menthol-flavored pod. A further five original JUUL products had been authorized in July 2025.
Read together with the enforcement guidance and the import alert revision, the pattern is consistent: the agency is building a narrower, better-defined legal category for vapor products, and trying to push everything outside it out of the supply chain.
What “no immediate operational changes” means for your purchase orders
It means the risk did not disappear on 28 September – it moved. Until a new rule is proposed, commented on and finalized, the practical compliance environment is the 2021 PMTA rule plus the May 2026 enforcement-priority guidance plus the revised import alert. That combination is what your shipment will actually meet at a port of entry this quarter.
It also means the announcement is a timing signal, not a legal event. Rulemaking takes months. A proposed rule, a public comment period and a final rule are the earliest realistic sequence; litigation could extend it further. Buyers who wait for the final text before adjusting their assortment will be buying into whatever supply conditions are left by then.
Import Alert 98-07: the part importers keep missing
Import Alert 98-07 was revised on 4 September 2026 and republished with a 18 September date, folding the agency’s May 2026 enforcement-priority guidance into the detention rules. Detention without physical examination (DWPE) remains in place for ENDS that lack the required marketing authorization. Field divisions are now directed to apply the risk-based framework, and Center for Tobacco Products concurrence is required in certain cases before a refusal decision is finalized.
The subtlety that costs money: a pending PMTA does not automatically remove a product from enforcement priority. The May 2026 guidance covers only products that have reached qualifying stages of review – certain accepted and filed applications, and qualifying supplemental PMTAs. For non-tobacco-flavored ENDS, the application must also contain information the FDA considers sufficient to evaluate the appropriate-for-the-protection-of-public-health standard. And a product can stay an enforcement priority for other reasons entirely, including a design or presentation the agency considers particularly appealing to youth.
For a purchase order, that means “we filed a PMTA” is not a shipping document. The three things worth asking a supplier for, in writing, are the receipt date of the submission, its current acceptance or filing status, and whether the SKU is treated as qualifying under the May 2026 guidance. If a supplier cannot put those three lines in an email, put the order somewhere else.
State directories: 17 states, and the deadlines that bite first
By August 2026, 17 states had enacted e-cigarette directory laws or similar systems, according to CDC Foundation figures; a study published in JAMA Network Open put the count at 16 as of June 2026. A directory law works like this: manufacturers certify products with the state, the state publishes the list of SKUs eligible for retail sale, and products that are absent from the list can be removed from stores – or trigger penalties – once enforcement begins.
The eligibility standards are not uniform. Some directories are tied closely to FDA marketing authorization or PMTA status. Others allow products that remain under federal review. That variation is exactly why a single national compliance sheet is useless. Additional implementation and enforcement deadlines are approaching in states including Pennsylvania and Iowa, which means SKU-level tracking across jurisdictions, not a one-time check.
What this looks like at SKU level
- One spreadsheet row per SKU, one column per state, values limited to eligible / pending / not listed.
- A named owner for updating it, because directory lists change after publication.
- A dated source link for each cell, so a buyer can defend an assortment decision during an audit.
- A rule for what happens to inventory of a SKU that drops off a list mid-quarter.
A five-step plan for Q4 2026 and Q1 2027
- Map every SKU to its current status. Authorization, qualifying under the May 2026 guidance, pending, or unlisted. If a SKU cannot be placed in one of those four buckets, treat it as unlisted.
- Separate the assortment into a compliant core and an opportunistic tail. Keep the core on long-cycle purchase orders. Keep the tail on short cycles, small quantities, and no forward commitments.
- Write regulatory-change language into supply contracts. Name the trigger (a final rule, a state directory removal, an import alert change), the notice period, and what happens to stock already produced.
- Ask for documentation before the first container, not after. Test reports, ingredient and nicotine declarations, batch traceability, and the paperwork your customs broker will actually need at entry.
- Decide your exposure limit in advance. Work out how many weeks of unauthorized-category inventory you are willing to carry through a rulemaking window, and hold that line when a good price arrives.
MOQ, trial orders and lead times in an uncertain window
Regulatory uncertainty usually shows up on the factory side as longer lead times and higher minimums, because factories shift to whoever commits volume. Two things help. First, split the order: a trial run of 2,000 pieces on one or two models gives you a real landed-cost figure and a compliance dry run without locking capital. Second, ask for mixed-flavor cartons with one full display case per flavor, which lets you test a shelf assortment across a single order instead of five.
On lead time, work backward from the regulatory dates rather than from the sailing schedule. If a rulemaking is likely in the first half of the year, stock positioned before that window is worth more than stock priced slightly cheaper and arriving after it.
Where WOOMI fits
WOOMI supplies vapor hardware for wholesale and private-label programs – including the Al Fakher Crown Bar 60K, VOZOL Pro T28 and ALIBARBAR Ingot 9000 lines – with MOQ 2,000 pieces, mixed-flavor orders accepted, and ready-to-ship stock dispatched in 3-5 business days. Authorization status in any specific market is a buyer decision, and we expect to be asked for the underlying specification and test documentation before a first order; that documentation is available on request rather than after the fact.
For buyers who need their own brand on the device, the OEM and ODM route is usually the better answer to a shifting rulebook: you control the specification, the labeling and the market you certify for, instead of reselling whatever configuration is already in a warehouse. Details are at WOOMI OEM/ODM programs, and current stock is listed at ready-to-ship disposable vapes.
FAQ
Is my disposable vape illegal in the US right now?
Selling a vapor product without FDA marketing authorization is unlawful, and it has been since the PMTA rule took effect in 2021. What has changed in 2026 is how the FDA prioritizes enforcement, and now how the framework itself may be rewritten. Products whose applications have reached qualifying stages under the May 2026 guidance are generally not an enforcement priority – but that is enforcement discretion, not authorization, and it does not apply to every product with a filing.
Does a pending PMTA protect a shipment at the border?
Not automatically. Import Alert 98-07 still permits detention without physical examination for ENDS lacking marketing authorization, and a pending application does not remove a product from enforcement priority unless it meets the conditions in the May 2026 guidance. Ask your supplier for the submission receipt date and acceptance or filing status before shipping.
What documents should I request before placing a wholesale order?
At minimum: product specification sheet, ingredient and nicotine declaration, test reports for the battery and device, batch traceability, and the commercial documents your broker needs at entry (invoice, packing list, bill of lading or air waybill, commodity code, net liquid volume, country of origin). If you sell into a state with a directory law, add the manufacturer certification that places the SKU on that list.
Should I hold off on inventory until the new rule is published?
No – holding off entirely just hands the window to competitors. The workable position is a compliant core on normal cycles, a small opportunistic tail on short cycles, and a written exposure limit you are willing to carry while the rule is pending.
What is the minimum order and lead time?
MOQ is 2,000 pieces per model, mixed flavors accepted with one full display case per flavor, and ready-to-ship stock usually dispatches in 3-5 business days. Private-label and OEM programs follow different minimums and timelines, which we quote per specification.
Next step
If you are rebuilding a US assortment for Q1 2027 and want the specification and documentation pack before you commit, send the models and target states you are working with through our contact page. We will come back with availability, tiered pricing, lead times and the compliance documents we hold. General sourcing questions are also answered at WOOMI FAQ.